Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs …

Jul 27, 2022  · BIOCON GROUP “We have had a strong start to the year. At a consolidated level, y-o-y revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics …


Install CouponFollow Chrome Extension   CouponFollow Extension

23%
OFF

Biocon Q1FY23 Revenue At Rs 2,217 Cr, Up 23%; Net Profit At Rs …

2 weeks from now

Jul 27, 2022  · BIOCON GROUP “We have had a strong start to the year. At a consolidated level, y-o-y revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics …

biocon.com

23%
OFF

Biocon Q1FY23 Revenue Up By 23% At Rs 2,217 Cr | Siliconindia

2 weeks from now

Jul 28, 2022  · Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a …

siliconindia.com

29%
OFF

Biocon Quarterly Revenues For Biosimilars Up 29%

2 weeks from now

Jul 28, 2022  · The revenues for the parent company improved by Rs 2217 Crore ($278 million) year over year. Biocon’s net profit went up Rs 144 Crore ($18 million), about 71% year over …

centerforbiosimilars.com

23%
OFF

Biocon Q1FY23 Revenue Witnessed 23% Increase – THIP Media

2 weeks from now

Jul 28, 2022  · Bengaluru, July 27 (IANS) Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at …

thip.media

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Biocon, Covid

2 weeks from now

Bengaluru July 27 : Global Biopharmaceuticals Company Biocon On Wednesday Reported 23 Per Cent Rise In Revenue For The First Quarter Of Financial Year 2023 At Rs 2 217 Crore.We …

telugustop.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Sarkaritel.com

2 weeks from now

Bengaluru, July 28 (IANS) Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs […]

sarkaritel.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Investing.com India

2 weeks from now

Jul 27, 2022  · Read Biocon Q1FY23 revenue up 23% at Rs 2,217 cr By IANS. Biocon Q1FY23 revenue up 23% at Rs 2,217 cr. Download the App. More markets insights, more alerts, more …

investing.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Smetimes.in

2 weeks from now

Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a strong start to …

smetimes.in

5%
OFF

Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …

2 weeks from now

Jan 30, 2025  · Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, …

indiatimes.com

36%
OFF

Biocon Q3FY23 Revenue At Rs 3,020 Cr, Up 36%; Biosimilars Up …

2 weeks from now

Q3FY23 revenue at Rs 786 Crore, up 23% (YoY) from Rs 641 Crore in Q3FY22. Business Performance. Syngene’s Q3FY23 results reflect positive performances across all divisions. Its …

bioconbiologics.com

23%
OFF

Biocon Q1FY23 Revenue At Rs 2,217 Cr, Up 23%; Net Profit At Rs …

2 weeks from now

Jul 27, 2022  · Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%. Wed, 27-Jul-2022 Posted by: Biocon Biologics ...

bioconbiologics.com

17%
OFF

Q3 Results Highlights: Bajaj Holdings' Revenue Up 17% ... - CNBCTV18

2 weeks from now

Jan 30, 2025  · Biocon’s financial performance for Q3 FY25 was in line with expectations.However, the year-on-year comparison is impacted by one-time gains recorded in Q3 FY24. In the …

cnbctv18.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025  · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

96%
OFF

Biocon Q3 Results: Profit Plummets 96%; Misses Estimates

2 weeks from now

Jan 30, 2025  · Revenue declined 3.4% to Rs 3,821 crore. Biocon Ltd.'s disappointing Q3FY25 performance was largely due to exceptional items, with adjusted net profit standing at Rs 13 …

ndtvprofit.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Thenewsmen.co.in

2 weeks from now

Jul 27, 2022  · We have had a strong start to the year. At a consolidated level, YoY revenues grew 23 per cent backed by robust growth in both Biosimilars (29 per cent) and Generics (19 per …

thenewsmen.co.in

23%
OFF

Biocon Q2FY23 Revenue At Rs 2,384 Cr, Up 23%; Core EBITDA At …

2 weeks from now

Nov 14, 2022  · We reported a strong consolidated revenue growth of 23% YoY for Q2FY23 at Rs 2,384 Crore driven by 34% growth in Biosimilars, 26% in Research Services and 18% in the …

biocon.com

59%
OFF

Biocon Q4FY23 Revenue At Rs 3,929 Cr, Up 59%; Biosimilars Up …

2 weeks from now

FY23 Revenue at Rs 11,550 Cr, Up 38%; EBITDA at Rs 2,888 Cr, Up 32% Net Profit ... Bengaluru, Karnataka, India: May 23, 2023: Biocon Ltd (BSE code: 532523, NSE: BIOCON), …

biocon.com

23%
OFF

Biocon Q1FY23 Revenue At Rs 2,217 Cr, Up 23%; Net Profit At …

2 weeks from now

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25% Biosimilars Up 29%; Generics Up 19%; Research Services Up …

biocon.com

FAQs about Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs … Coupon?

How did Biocon Group perform in q1fy22?

BIOCON GROUP “We have had a strong start to the year. At a consolidated level, y-o-y revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics (19%). Core EBITDA grew 25% and margin improved to 31% compared to 30% in Q1FY22. and Net Profit grew 71% to Rs 144 Crore. ...

How did Biocon perform in q3fy25?

Biocon reported 96% year-on-year (YoY) drop in net profit to Rs 25 crore in Q3FY25. The company reported net profit of Rs 660 crore during Q3FY24, aided by an exception item of Rs 566 crore. Revenue from operations rose 10% YoY to Rs 3821 crore in Q3FY25. EBITDA for the quarter rose 16% YoY to Rs 787 crore, representing an EBITDA margin of 20%. ...

How will Biocon's R&D investments drive its future growth?

Biocon reported Research Services revenues of Rs 786 crore and Generics business revenues of Rs 718 crore, which grew 23% and 18%, respectively. Net R&D investments amounted to Rs 337 crore this quarter, driven by the advancement of Biocon’s research pipeline. ...

How did Biocon perform in a quarter last year?

In the corresponding quarter last year, Biocon’s earnings included revenue from the Branded Formulations India (BFI) business, which has since been divested, along with an income of ₹350 crore from the partial divestment of BFI units by Biocon Biologics and a gain of ₹456 crore from Biocon’s stake dilution in Bicara Therapeutics. ...

How did Biocon biologics perform in a year?

Biocon Biologics’ revenue for the full year stood at Rs 5,584 Crore, reporting a growth of 61%. EBITDA for the year stood at Rs 1,338 crore, a year-on-year growth of 32%. Core EBITDA grew by 68% to Rs 2,216 crore. ...

Is Biocon a biopharmaceutical company?

Biocon Ltd is an innovation-led global biopharmaceuticals company based in Bengaluru, Karnataka, India. The company announced its consolidated financial results for the third quarter ended December 31, 2022. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension